Organization
Nagoya University Hospital Lecturer of hospital
Title
Lecturer of hospital
URAKAWA Hiroshi
Degree 1
-
博士（医学） （ 2011.3 名古屋大学 ）
Research History 10
-
Nagoya University Nagoya University Hospital Lecturer of hospital
2022.4
-
Pharmaceuticals and Medical Devices Agency
2020.4 - 2022.3
-
Nagoya University Hospital Clinical Oncology and Chemotherapy Lecturer of hospital
2017.7 - 2020.3
-
名古屋大学医学部附属病院 整形外科 病院講師
2016.4 - 2017.6
Country：Japan
-
名古屋大学大学院医学系研究科 小児集中治療学寄附講座 寄附講座講師
2015.6 - 2016.3
Country：Japan
Education 2
-
Nagoya University Graduate School, Division of Medical Sciences
- 2011.3
Country： Japan
-
University of Occupational and Environmental Health, Japan Faculty of Medicine
- 1999.3
Country： Japan
Professional Memberships 3
-
中部日本整形外科・災害外科学会
-
日本整形外科学会
-
日本臨床腫瘍学会
Papers 48
-
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610 Reviewed International journal
Urakawa, H; Nagano, A; Machida, R; Tanaka, K; Kataoka, T; Sekino, Y; Nishida, Y; Takahashi, M; Kunisada, T; Kawano, M; Yoshida, Y; Takagi, T; Sato, K; Hiruma, T; Hatano, H; Tsukushi, S; Sakamoto, A; Akisue, T; Hiraoka, K; Ozaki, T
JAPANESE JOURNAL OF CLINICAL ONCOLOGY Vol. 52 ( 9 ) page： 1021 - 1028 2022.9
-
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study Reviewed International journal
Urakawa, H; Kawai, A; Goto, T; Hiraga, H; Ozaki, T; Tsuchiya, H; Nakayama, R; Naka, N; Matsumoto, Y; Kobayashi, E; Okuma, T; Kunisada, T; Ando, M; Ueda, T; Nishida, Y
CANCER SCIENCE Vol. 111 ( 9 ) page： 3303 - 3312 2020.9
-
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study Reviewed International journal
Urakawa, H; Ando, Y; Hase, T; Kikumori, T; Arai, E; Maeda, O; Mitsuma, A; Sugishita, M; Shimokata, T; Ikuta, K; Ishiguro, N; Nishida, Y
INTERNATIONAL JOURNAL OF CANCER Vol. 146 ( 12 ) page： 3504 - 3515 2020.6
-
A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610. Reviewed International journal
Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T
Japanese journal of clinical oncology Vol. 49 ( 4 ) page： 379 - 382 2019.4
-
Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study Reviewed International journal
Urakawa Hiroshi, Yonemoto Tsukasa, Matsumoto Seiichi, Takagi Tatsuya, Asanuma Kunihiro, Watanuki Munenori, Takemoto Akira, Naka Norifumi, Matsumoto Yoshihiro, Kawai Akira, Kunisada Toshiyuki, Kubo Tadahiko, Emori Makoto, Hiraga Hiroaki, Hatano Hiroshi, Tsukushi Satoshi, Nishida Yoshihiro, Akisue Toshihiro, Morii Takeshi, Takahashi Mitsuru, Nagano Akihito, Yoshikawa Hideki, Sato Kenji, Kawano Masanori, Hiraoka Koji, Tanaka Kazuhiro, Iwamoto Yukihide, Ozaki Toshifumi
WORLD JOURNAL OF SURGICAL ONCOLOGY Vol. 16 ( 1 ) page： 160 2018.8
Books 2
-
新臨床腫瘍学 改訂第7版
（ Role： Joint editor）
株式会社南江堂 2024
-
外来化学療法室がん薬物療法カンファレンス Reviewed
安藤雄一、足立康則、下方智也、本多和典、柴田剛志、前田修、満間綾子、井上めぐみ、森田佐知、松岡歩、林直美、土居崎佐代子、浦川浩、十九浦宏明、杉下美保子、山本英子（ Role： Contributor）
南山堂 2015
Presentations 34
-
Postoperative brain metastases in soft tissue sarcomas International conference
Urakawa H, Tsukushi S, Kozawa E, Ikuta K, Hamada S, Ishiguro N, Nishida Y
19th Annual meeting Connective Tissue Oncology society
-
単発性骨転移臨床成績の検討
浦川浩, 西田佳弘, 筑紫聡, 満間綾子, 杉下美保子, 下方智也, 小澤英史, 新井英介, 二村尚久, 安藤雄一, 石黒直樹
第47回日本整形外科学会骨・軟部腫瘍学術集会
-
骨転移患者におけるゾレドロン酸投与後腎障害の検討
浦川浩, 筑紫聡, 満間綾子, 杉下美保子, 下方智也, 小澤英史, 新井英介, 二村尚久, 安藤雄一, 石黒直樹, 西田佳弘
第87回日本整形外科学会学術総会
-
上腕骨発生孤立性骨嚢腫の治療成績に影響する因子の検討
浦川浩, 筑紫聡, 細野幸三, 杉浦英志, 山田健志, 山田芳久, 小澤英史, 新井英介, 二村尚久, 石黒直樹, 西田佳弘
第87回日本整形外科学会学術総会
-
Prognostic impact of trunk location in patients with non-small round cell soft tissue sarcoma International conference
Urakawa H, Tsukushi S, Kozawa E, Arai E, Futamura N, Ishiguro N, Nishida Y.
The 10th Asia Pacific Musculoskeletal Tumor Society Meeting,
KAKENHI (Grants-in-Aid for Scientific Research) 8
-
Grant number：17K10963 2017.4 - 2020.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
URAKAWA HIROSHI
Authorship：Principal investigator Grant type：Competitive
Grant amount：\4550000 （ Direct Cost: \3500000 、 Indirect Cost：\1050000 ）
To clarify the relationship between tumor immunity and extracellular matrix / receptor / intracellular signal network mediated by hyaluronan and to establish new immunotherapy targeting in bone and soft tissue sarcoma, we evaluated the relationship between immune checkpoint molecules and hyaluronan network in bone and soft tissue sarcoma. Abundant extracellular matrix was observed in bone and soft tissue sarcoma cells, and a certain relationship between extracellular matrix/ receptor / intracellular signal network and immune checkpoint molecules was observed. Abundant expression of hyaluronan was observed in bone and soft tissue sarcoma tumor tissue, and the immune cell infiltration and immune checkpoint molecule expression were observed in certain type of sarcomas.
-
Grant number：23K08696 2023.4 - 2026.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Authorship：Principal investigator Grant type：Competitive
Grant amount：\4680000 （ Direct Cost: \3600000 、 Indirect Cost：\1080000 ）
-
The role of cathepsin K in the bone and lung metastases
Grant number：15K10438 2015.4 - 2018.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
KOZAWA EIJI, YOSHIDA Masahiro, HAYASHI Takuma
Authorship：Coinvestigator(s) Grant type：Competitive
CatK synthesized by osteoclasts and/or tumor cells, tumor microenvironmental macrophage/fibroblasts to be an obvious candidate for a key enzyme involved in the destruction of bone matrix. To establish a murine bone metastasis model, a needle with syringe was used to inject MDA-MB-231 cells and Lewis lung cancer cells into the tibia of mice. Osteolytic lesions progressed markedly at tibia of mice. Scion image analysis revealed that the size of the osteolytic increased from 2 to 4 weeks. The expansion of bone lytic areas of tibia with Lewis lung cancer progressed rapidly for 2 weeks. Histological stain for bone tumor was performed.
The sample included 50 patients with lung tumors and 19 patients with musculoskeletal tumors. The overall 5-year survival rate of the patients was 57.7%. Pre-operative MRI evaluation is helpful to determine whether tumors should be resected with adjacent bone or not. -
Clinical significance of sarcopenia in cancer chemotherapy
Grant number：26460626 2014.4 - 2018.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Ando Yuichi
Authorship：Coinvestigator(s) Grant type：Competitive
The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.
-
Image-guided cryoablation for palliative therapy of skeletal metastases.
Grant number：26462260 2014.4 - 2018.3
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Tsukushi Satoshi, YOSHIDA Masahiro, HAYASHI Takuma, HASEGAWA Hiroaki, SUZUKI Syuichiro
Authorship：Coinvestigator(s) Grant type：Competitive
The aim of this study was to investigate local control of in non-small round cell soft tissue sarcomas.The overall survival rates at 5 years were 85.7%.The local recurrence-free survival rates at 5 years were 89.8% (positive margin: 72.5%, margin of 2 mm or less: 60.6%). In the univariate analysis size, depth, histological grade and positive margin were significant unfavorable prognostic factors for local recurrence free survival. In multivariate analyses, we showed that positive margin and histological grade were significant independent predictors of local recurrence free survival.Positive margin and histological grade were important prognostic factors for local recurrence. Close margin (2 mm or less) in the longitudinal direction was associated with a high risk of local recurrence.The reach of the local treatment should be decided based on these factors.